Table 1 Cough severity in patients with post-COVID-19 cough measured by number of paroxysms, visual analogue scale (VAS), cough severity index, and cough quality-of-life questionnaire after 14-day treatment with montelukast 10 mg (n = 68 patients)

Number of paroxysms/days

12 ± 3.1

3 ± 1.2*

10 ± 4.1#

*#< 0.01

Cough severity VAS

76 ± 19

12 ± 6*

66 ± 12#

< 0.001

Cough severity index

21 ± 2

4 ± 1.1*

20 ± 5#

< 0.01

Cough quality of life questionnaire

87 ± 4.9

18 ± 2.5*

98 ± 2#

< 0.01

Days needed for improvement

-

5 ± 1.4

10 ± 1.5#

#< 0.05

Side effects^a

-

6 (18.7)

-

N/A